We need to bring together our real-world data and our reimbursement systems to recognize the fact that a lot of what could be gained by precision medicine is going to be based on a lot of research, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.
We need to bring together our real-world data and our reimbursement systems to recognize the fact that a lot of what could be gained by precision medicine is going to be based on a lot of research, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.
Transcript
What current challenges are there in precision medicine?
I think that the number of drugs that are either FDA approved or compendium listed based on precision medicine test is still fairly small; maybe a couple dozen or less. There are many more drugs in the pipeline, of course, but a lot of those will crash and burn on the way and never make it. So, there is a lot of work to be done in drug development to identify drugs that are effective and tolerable for a target, and we’re still very much in the research world realm of development.
We need to bring together our real-world data and our reimbursement systems to recognize the fact that a lot of what could be released and gained by precision medicine is going to be based on a lot of research, and unless we find a way to fund it at a time when we’re still in the research mode, you’d be very slow to realize the benefits of precision medicine.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More